Detection and preliminary characterization of CD8+T lymphocytes specific for Wilms’ tumor antigen in patients with non-Hodgkin lymphoma

Israyelyan, Anna; Rosa, Corinna La; Tsai, Wei-Feng; Kaltcheva, Teodora; Srivastava, Tumul; Aquino, Lia; Li, Jianqiang; Kim, Young; Palmer, Joycelynne; Streja, Leanne; Senitzer, David; Zaia, John A.; Rosenwald, Andreas; Forman, Stephen J.; Nakamura, Ryotaro; Diamond, Don J.

doi:10.3109/10428194.2013.783910

Cited by 5 publications

(2 citation statements)

References 45 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also higher SPARC expression was noted in tumours of the tongue rather than tumors of the lips. The SPARC expression also changes according to the grade of the tumor [37].…”

Section: Resultsmentioning

confidence: 99%

Deciphering the Genetic Alterations in SPARC Gene Family and Its Association with HNSCC

Vidyashri

Girija

Paramasivam

et al. 2020

JPRI

View full text Add to dashboard Cite

The aim of this study is to identify the genetic alteration in SPARC gene family and its association with head and neck squamous cell carcinoma (HNSCC). Head and neck cancer is a set of cancerous lesions arising from the squamous cell of the mucous membrane of the oral cavity, nose throat, larynx and pharynx. SPARC gene encodes for cysteine rich acid matrix metalloprotein, osteonectin whose expression in metastatic OSCC (Oral squamous cell carcinoma) was found to be higher. This expression pattern also correlated with the worst pattern of invasion and differentiation of OSCC tumors. In line with the above facts, the present study was carried out to ascertain the gene alterations and their consequences. Also the putative association of gene alterations with HNSCC was analyzed using computational tools. The Cancer Gene Atlas (TCGA, Firehose Legacy) dataset hosted by the cBioportal server was used in the present study. The non-synonymous variants identified were further assessed for protein stability and pathogenicity employing IMutant and PROVEAN tools. Gene amplification was observed in the FSTL1 gene, which was also shown to present with the highest frequency of gene alterations (5%) among eight genes. Furthermore, the expression of the FSTL1 gene was found to differ significantly among different grades of HNSCC. In conclusion, the study throws light on the possible association of the FSTL1 gene of the SPARC family with HNSCC.

show abstract

“…Also higher SPARC expression was noted in tumours of the tongue rather than tumors of the lips. The SPARC expression also changes according to the grade of the tumor [37].…”

Section: Resultsmentioning

confidence: 99%

Deciphering the Genetic Alterations in SPARC Gene Family and Its Association with HNSCC

Vidyashri

Girija

Paramasivam

et al. 2020

JPRI

View full text Add to dashboard Cite

show abstract

“…Israyelyan et al [28] reported that a large percentage of patients with non-Hodgkin's lymphoma (NHL) maintained WT1-specific T cells and that WT1 mRNA transcripts were detected in diseased lymph node tissues of many of NHL patients, which suggests that NHL could also be a target disease. In addition, myeloproliferative neoplasms may qualify as a target because of the inherent WT1 expression [29].…”

Section: Potential Target Hematological Malignancies Other Than Aml Amentioning

confidence: 99%

Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy

et al. 2017

View full text Add to dashboard Cite

The identification of human Wilms' tumor gene 1 (WT1) protein-derived cytotoxic T lymphocyte (CTL) epitopes and the in vivo efficacy of WT1 peptide-based immunotherapy in a mouse model were reported in 2000. This successful basic research led to clinical studies of a WT1 peptide vaccine, and a positive impact on clinical response was first demonstrated in 2003 in the form of a reduction in blast cells of vaccine-treated patients with myelodysplastic syndromes (MDS). Since then, data on WT1 peptide vaccine-treated patients with immunological and/or clinical response have been accumulated. MDS and acute myeloid leukemia were the major target diseases to provide proof of concept for the therapeutic potential of the WT1 peptide vaccine. WT1 vaccination-induced clinical responses or usefulness were also shown for chronic myeloid leukemia, multiple myeloma, and acute lymphoblastic leukemia, as well as various types of solid cancers. Non-Hodgkin's lymphoma and myeloproliferative neoplasms may also be target diseases because of their WT1 expression. Of note, recent clinical studies have demonstrated that patients with hematological malignancies who have minimal residual disease after chemotherapy or allogeneic hematopoietic stem cell transplantation may be cured by WT1 peptide vaccination. Further enhancement of the efficacy and usefulness of the WT1 peptide vaccine is expected.

show abstract

Wilms tumor gent 1 (WT1)-specific adoptive immunotherapy in hematologic diseases

Jiang

et al. 2021

International Immunopharmacology

View full text Add to dashboard Cite

Detection and preliminary characterization of CD8+T lymphocytes specific for Wilms’ tumor antigen in patients with non-Hodgkin lymphoma

Cited by 5 publications

References 45 publications

Deciphering the Genetic Alterations in SPARC Gene Family and Its Association with HNSCC

Deciphering the Genetic Alterations in SPARC Gene Family and Its Association with HNSCC

Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy

Wilms tumor gent 1 (WT1)-specific adoptive immunotherapy in hematologic diseases

Contact Info

Product

Resources

About